On 11 August 2025, the Secretary of Health (SOH) fully concurs with the Health Technology Council recommendation on the government financing of the following health technologies, through the Department of Health (DOH) Department Circulars 2025-0338, 2025-0339, and 2025-0340:

1. Newborn Pulse Oximetry Screening (NPOS) as a test for critical congenital heart disease (CCHD) among asymptomatic, apparently healthy newborns
2. HIV Self Test Kit for screening HIV infection in adults belonging to HIV and sexually transmitted infection for key populations
3. HIV/Syphilis Duo Test for screening of HIV and Syphilis infection in pregnant women as part of antenatal care, ideally during the first trimester
4. In Vitro Quantitative HIV Nucleic Acid Test (HIV NAT-1) for screening and diagnosis of HIV type 1 infection in HIV-exposed infants and children
5. Interferon gamma release ELISA assay (IGRA) for screening of latent/ asymptomatic tuberculosis
6. Chip-based Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Test for diagnosis of drug-susceptible tuberculosis (DS-TB)
7. Cartridge-based RT-PCR Test for diagnosis of rifampicin-resistant tuberculosis (RR-TB)
8. Chip-based RT-PCR Test for diagnosis of RR-TB
9. Line Probe Assay (LPA) for diagnosis of multidrug-resistant tuberculosis (MDR-TB)
10. LPA for diagnosis of extensively drug-resistant tuberculosis (XDR-TB)
11. Cartridge-based RT-PCR Test for diagnosis of XDR-TB
12. Lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosis of active tuberculosis infection in human immunodeficiency virus (HIV) patient

For the full details on the HTA Council Final Recommendation, such as considerations and evidence, please see the above links, or refer to the Omnibus HTA Tracker.